Febuxostat-Controlled, Double-Blind, Comparative Study of... | NCT03372200

Studies
Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout

NCT03372200

Sponsor

Mochida Pharmaceutical Company, Ltd.

Status

Completed

Last Update Posted

Sep 24, 2018Actual

Enrollment

203Actual

Phase

Phase 3

Conditions

Hyperuricemia With or Without Gout

Interventions

FYU-981
Febuxostat

Countries

Japan

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Sep 2018

Overall Recruitment Status or Expanded Access Status

Completed

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Jan 9, 2018Actual

Primary Completion Date

Jun 4, 2018Actual

Completion Date

Jul 5, 2018Actual

First Submitted Date

Dec 10, 2017

First Submission Date that Met QC Criteria

Dec 12, 2017

First Posted Date

Dec 13, 2017Actual

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Sep 21, 2018

Last Update Posted Date

Sep 24, 2018Actual

Name	Class
Fuji Yakuhin Co., Ltd.	INDUSTRY

Oversight Module

Has Data Monitoring Committee (DMC)

Not provided

Is FDA Regulated Drug

Is FDA Regulated Device

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

FYU-981 or Febuxostat are administrated to hyperuricemia patients (underexcretion and mixed types) with or without gout for 14 weeks to compare the efficacy and safety of these drugs by the method of multicenter, randomized, double-blind, ascending dose regimen.

Detailed Description

Not provided

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Phase 3

Interventional Study Design

Allocation

Biospecimen

No data available

No data is available for this block.

Enrollment

203Actual

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
FYU-981	Experimental		Drug: FYU-981
Febuxostat	Active Comparator		Drug: Febuxostat

Interventions

Name	Type	Description	Arm Group Labels	Other Names
FYU-981	Drug	Oral daily dosing for 14 weeks	FYU-981
Febuxostat

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Percent reduction from baseline in serum urate level at the final visit	Percent reduction from baseline in serum urate level at the final visit	14 weeks

Secondary Outcomes

Not provided

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Serum urate level:
- >= 7.0mg/dL in patients with gouty nodule or with history of gout, or >= 8.0mg/dL in patients with hypertension, diabetes or metabolic syndrome, or >= 9.0mg/dL
Disease type in the classification of hyperuricemia: Uric acid-underexcretion type or mixed type
Outpatients

Exclusion Criteria:

Gouty arthritis within 14 days before randomized allocation
Secondary hyperuricemia
HbA1c: >= 8.4%
Clinically significant cardiac, hepatic, renal, hematologic or endocrine disease
Kidney calculi or clinically significant urinary calculi
AST: >= 100 IU/L or ALT: >= 100 IU/L
eGFR: < 30 mL/min/1.73m^2
Systolic blood pressure: >= 180 mmHg or diastolic blood pressure: >= 110 mmHg

Accepts Healthy Volunteers

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

20 Years

Maximum Age

Not provided

Standard Ages

AdultOlder Adult

Study Population

Not provided

Sampling Method

Not provided

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Name	Affiliation	Role
Kazuki Furuno	Clinical Research Department	Study Director

Locations

Facility	Status	City	State	ZIP	Country	Contacts
Mochida Investigational sites		Tokyo			Japan

Intervention Browse Module

MeSH Terms

ID	Term
C000706811	dotinurad
D000069465	Febuxostat

Ancestor Terms

ID	Term
D013844	Thiazoles
D013457	Sulfur Compounds
D009930	Organic Chemicals
D001393	Azoles

Browse Leaves

Not provided

Browse Branches

Not provided